VIDEO: Inrig discusses outcomes, developments for adults with IgA nephropathy
Click Here to Manage Email Alerts
Key takeaways:
- The first study examined sparsentan to treat proteinuria in adults with IgA nephropathy.
- The second study assessed the rate of loss of eGFR and time-averaged proteinuria in this cohort.
PHILADELPHIA — Sparsentan was shown to be safe and well-tolerated, and reduced proteinuria in adults with IgA nephropathy, according to studies presented at ASN Kidney Week.
In this video interview with Healio, Jula K. Inrig, MD, chief medical officer of Travere Therapeutics Inc., discussed findings from a preliminary trial that investigated the efficacy the novel, non-immunosuppressive, single-molecule dual endothelin angiotensin receptor antagonist as first-line therapy in patients newly diagnosed with IgA nephropathy.
Patients in the open-label, multicenter study had median proteinuria of 1.4 g/d, mean eGFR of 67 mL/min/1.73 m2 and systolic/diastolic blood pressure of 122/80 mmHg at baseline. According to results of the single-arm, exploratory trial, sparsentan reduced proteinuria more than 70% for 12 weeks.
Based on the findings, Inrig said sparsentan may be a “great potential option for early first-line treatment ... And we will continue to analyze this data over time. We’ll have kidney biopsy data repeated over time in the future.” She said, “The important thing that people care about with regard to treating IgA nephropathy is, ‘Can you keep patients off dialysis? What’s the progression of the disease over time?’ That’s another poster that we presented today.”
Inrig also discussed outcomes from a separate trial assessing eGFR loss and time-averaged proteinuria in adults with IgA nephropathy progressing to kidney failure. The preliminary trial studied patients enrolled in the U.K. National Registry of Rare Kidney Diseases with biopsy-proven IgA nephropathy and follow-up data spanning early to late chronic kidney disease. Researchers compared the extent of patients’ proteinuria and eGFR decline prior to and after entering CKD stage 3B. Results showed eGFR decline was rapid and suggest slope measurements in early disease stages may be useful in estimating future eGFR loss.
“What that tells us is that we can predict that if a patient is able to preserve more kidney function over time, as we showed with sparsentan therapy, ... we can predict that out to how much we can preserve kidney function over 5, 10, 15 years.”
Reference:
Inrig JK, et al. SA-PO901. Presented at: ASN Kidney Week; Nov. 1-5, 2023; Philadelphia.
Inrig JK, et al. SA-PO948. Presented at: ASN Kidney Week; Nov. 1-5, 2023; Philadelphia.
Collapse
Click Here to Manage Email Alerts